GlassScriptPhysician profile
Amit K Singh
NPI 1396932463
$5,140.59
in general payments reported to CMS, 2019-2025
48 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $653 · 2021: $801 · 2022: $1,220 · 2023: $1,106 · 2024: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478 · Education: $72.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.14 |
| Education | $72.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $702.95 | 2019-2024 | |
| Abbvie INC. | $628.94 | 2021-2024 | Ubrelvy, Vraylar, Qulipta |
| Glaxosmithkline, LLC. | $488.39 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $479.00 | 2019-2024 | Wegovy, Saxenda |
| Astellas Pharma US INC | $281.13 | 2020-2024 | Veozah, Myrbetriq |
| Novartis Pharmaceuticals Corporation | $258.41 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $241.03 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $194.15 | 2019-2024 | Farxiga, Airsupra |
| Surgical Specialties Corporation (US), INC. (Dba Corza Medical) | $164.99 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.15 | 2020-2023 | Xifaxan, Cycloset, Trulance |
| Allergan, INC. | $91.98 | 2019-2020 | |
| Amgen INC. | $87.67 | 2019-2023 | Prolia, Evenity |
| Ironwood Pharmaceuticals, INC | $87.50 | 2021-2023 | Linzess |
| Currax Pharmaceuticals LLC | $81.16 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $80.02 | 2019-2021 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.